Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension.
This paper deals with some changes at the cardiac and aortic levels observed in normotensive rats and in hypertensive rats and turkeys by using two different beta-blockers, namely propranolol and oxprenolol. Chronic treatment with propranolol induced in the heart of normotensive rats a shift in the ventricular myosin pattern toward the "slow" V2 and V3 isoforms which are characterized by a reduced oxygen consumption. Oxprenolol treatment did not modify the blood pressure levels in the renal hypertensive rats nor in the spontaneously hypertensive turkeys. Nevertheless, in both experimental models a substantial modification of the media and intima, respectively, took place. In untreated hypertensive and normal rats the thickness of the aortic media was significantly higher than that of the treated ones, therefore suggesting a direct effect of oxprenolol on the smooth muscle cells of the aortic media. In the spontaneously hypertensive turkeys the atherosclerotic plaques appeared to be more frequent and thicker than those found in the oxprenolol-treated animals. These two experiments demonstrate that beta-blockers can prevent the development of hypertrophy of the media and decrease both the incidence and severity of intimal proliferations independently of blood pressure control. It therefore appears that the well-known myocardial protective effect played by beta-blockers, which mainly consists of a reduced myocardial oxygen consumption, is certainly obtained by reducing blood pressure and heart rate but also by changing the contractile protein pattern. In addition, an indirect myocardial protective effect could be exerted by beta-blockers at the vascular level by preventing medial hypertrophy and the development of atherosclerosis.
Pauletto
P
P
Institute of Clinical Medicine, University of Padua, Italy.
Vescovo
G
G
Scannapieco
G
G
Pessina
A C
AC
Dal Palù
C
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D006332:Cardiomegaly / Q000517:prevention & control; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000503:physiopathology; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009206:Myocardium / Q000201:enzymology; D009929:Organ Size / Q000187:drug effects; D010096:Oxprenolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D014422:Turkeys
D000319:Adrenergic beta-Antagonists; D010096:Oxprenolol; D011433:Propranolol; D000252:Calcium-Transporting ATPases